UPDATE: A pocket guide to the future EU clinical trials environment
This article was originally published in SRA
On 22 January, the European Parliament's environment, public health and food safety (ENVI) committee will vote on the text of the proposed EU Clinical Trials Regulation that was agreed by member states in December 20131-3.
You may also be interested in...
The UK life sciences trade group says the “ill-considered” guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.